Literature DB >> 12215428

Suppression of nuclear factor-kappa B activity by nitric oxide and hyperoxia in oxygen-resistant cells.

William R Franek1, Yalamanchali C Chowdary, Xinchun Lin, Maowen Hu, Edmund J Miller, Jeffrey A Kazzaz, Pasquale Razzano, John Romashko, Jonathan M Davis, Pramod Narula, Stuart Horowitz, William Scott, Lin L Mantell.   

Abstract

Inhaled nitric oxide (iNO) is used clinically to treat pulmonary hypertension in newborns, often in conjunction with hyperoxia (NO/O2). Prolonged exposure to NO/O2 causes synergistic lung injury and death of lung epithelial cells. To explore the mechanisms involved, oxygen-resistant HeLa-80 cells were exposed to NO +/- O2. Exposure to NO and O2 induced a synergistic cytotoxicity, accompanied with apoptotic characteristics, including elevated caspase-3-like activity, Annexin V incorporation, and nuclear condensation. This apoptosis was associated with a synergistic suppression of NF-kappaB activity. Cells lacking functional NF-kappaB p65 subunit were more sensitive to NO/O2 than their wild type counterparts. This injury was partially rescued by transfection with a p65 expression construct, suggesting an inverse relationship between NF-kappaB and susceptibility to the cytotoxicity of NO/O2. Despite the reduced NF-kappaB activity in cells exposed to NO +/- O2, IkappaBalpha was degraded, suggesting that pathways regulating the steady-state levels of IkappaB were not involved. However, exposure to NO/O2 caused a marked reduction in nuclear localization and an increase in protein carbonyl formation of NF-kappaB p65 subunit. These results suggest that NO/O2-induced apoptosis occurs by suppressing NF-kappaB activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215428     DOI: 10.1074/jbc.M202623200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Authors:  Clyde J Wright; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-06-06       Impact factor: 7.124

Review 2.  Balancing the risks and benefits of oxygen therapy in critically III adults.

Authors:  G R Scott Budinger; Gökhan M Mutlu
Journal:  Chest       Date:  2013-04       Impact factor: 9.410

Review 3.  Manipulation of gene expression by oxygen: a primer from bedside to bench.

Authors:  Clyde J Wright; Phyllis A Dennery
Journal:  Pediatr Res       Date:  2009-07       Impact factor: 3.756

4.  Cystic fibrosis transmembrane conductance regulator controls lung proteasomal degradation and nuclear factor-kappaB activity in conditions of oxidative stress.

Authors:  Emilie Boncoeur; Telma Roque; Elise Bonvin; Vinciane Saint-Criq; Monique Bonora; Annick Clement; Olivier Tabary; Alexandra Henrion-Caude; Jacky Jacquot
Journal:  Am J Pathol       Date:  2008-03-27       Impact factor: 4.307

5.  The α7 nicotinic acetylcholine receptor agonist GTS-21 improves bacterial clearance in mice by restoring hyperoxia-compromised macrophage function.

Authors:  Ravikumar A Sitapara; Daniel J Antoine; Lokesh Sharma; Vivek S Patel; Charles R Ashby; Samir Gorasiya; Huan Yang; Michelle Zur; Lin L Mantell
Journal:  Mol Med       Date:  2014-06-19       Impact factor: 6.354

Review 6.  Hyperoxia-induced signal transduction pathways in pulmonary epithelial cells.

Authors:  Tahereh E Zaher; Edmund J Miller; Dympna M P Morrow; Mohammad Javdan; Lin L Mantell
Journal:  Free Radic Biol Med       Date:  2007-01-17       Impact factor: 7.376

Review 7.  Nitric oxide and hyperoxic acute lung injury.

Authors:  Wen-Wu Liu; Cui-Hong Han; Pei-Xi Zhang; Juan Zheng; Kan Liu; Xue-Jun Sun
Journal:  Med Gas Res       Date:  2016-07-11

8.  Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.

Authors:  Nana O Wilson; Wesley Solomon; Leonard Anderson; John Patrickson; Sidney Pitts; Vincent Bond; Mingli Liu; Jonathan K Stiles
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.